IL143040A0 - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state

Info

Publication number
IL143040A0
IL143040A0 IL14304099A IL14304099A IL143040A0 IL 143040 A0 IL143040 A0 IL 143040A0 IL 14304099 A IL14304099 A IL 14304099A IL 14304099 A IL14304099 A IL 14304099A IL 143040 A0 IL143040 A0 IL 143040A0
Authority
IL
Israel
Prior art keywords
meta
stable crystalline
crystalline region
producing particles
particles
Prior art date
Application number
IL14304099A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL143040A0 publication Critical patent/IL143040A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
IL14304099A 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state IL143040A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (1)

Publication Number Publication Date
IL143040A0 true IL143040A0 (en) 2002-04-21

Family

ID=20413377

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14304099A IL143040A0 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Country Status (27)

Country Link
US (1) US6475524B1 (cs)
EP (1) EP1133285B1 (cs)
JP (1) JP4447169B2 (cs)
KR (1) KR100697780B1 (cs)
CN (1) CN1198592C (cs)
AT (1) ATE318583T1 (cs)
AU (1) AU767313B2 (cs)
BR (1) BR9915592A (cs)
CA (1) CA2349633C (cs)
CY (1) CY1105609T1 (cs)
CZ (1) CZ20011778A3 (cs)
DE (1) DE69930158T2 (cs)
DK (1) DK1133285T3 (cs)
EE (1) EE200100275A (cs)
ES (1) ES2258865T3 (cs)
HU (1) HUP0104182A2 (cs)
IL (2) IL143040A0 (cs)
IS (1) IS5946A (cs)
NO (1) NO20012514L (cs)
NZ (1) NZ511494A (cs)
PL (1) PL348523A1 (cs)
PT (1) PT1133285E (cs)
SE (1) SE9804000D0 (cs)
SK (1) SK7032001A3 (cs)
TR (1) TR200101424T2 (cs)
WO (1) WO2000030614A1 (cs)
ZA (1) ZA200103946B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
WO2002051381A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Substance poreuse et son procede de fabrication
ES2261469T5 (es) * 2001-07-02 2015-12-22 Micro & Nano Materials Sagl Proceso para producir micro y/o nanopartículas
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN1913882A (zh) * 2004-02-06 2007-02-14 Meda制药有限及两合公司 用抗胆碱能药单独或联合抗组胺药、磷酸二酯酶4抑制剂或皮质类固醇来治疗鼻炎
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
AU2008331967B2 (en) * 2007-12-07 2012-10-25 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
CN102892289B (zh) 2010-03-03 2015-03-25 尼昂克技术公司 包含单萜的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
BR112013015107B1 (pt) 2010-12-17 2022-03-22 Neonc Technologies Inc. Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
PT2968312T (pt) 2013-03-15 2018-04-19 Verona Pharma Plc Combinação de fármacos
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
EP3547836A4 (en) 2016-11-30 2020-08-05 Neonc Technologies Inc. PERILLYL ALCOHOL-3 BROMOPYRUVATE CONJUGATE AND METHOD OF TREATMENT OF CANCER
WO2019157195A1 (en) 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE69618938T2 (de) 1995-03-28 2002-10-31 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
KR100386055B1 (ko) 1997-03-20 2003-06-09 쉐링 코포레이션 분말 응집물의 제조방법

Also Published As

Publication number Publication date
PL348523A1 (en) 2002-06-03
PT1133285E (pt) 2006-06-30
CA2349633C (en) 2009-06-02
EP1133285A1 (en) 2001-09-19
IS5946A (is) 2001-05-18
BR9915592A (pt) 2001-08-07
DE69930158T2 (de) 2006-11-16
CN1198592C (zh) 2005-04-27
WO2000030614A1 (en) 2000-06-02
TR200101424T2 (tr) 2001-12-21
EE200100275A (et) 2002-10-15
KR100697780B1 (ko) 2007-03-21
SK7032001A3 (en) 2001-11-06
NZ511494A (en) 2003-11-28
CZ20011778A3 (cs) 2001-08-15
ZA200103946B (en) 2002-10-30
CA2349633A1 (en) 2000-06-02
IL143040A (en) 2009-09-01
EP1133285B1 (en) 2006-03-01
KR20010080534A (ko) 2001-08-22
DE69930158D1 (de) 2006-04-27
NO20012514L (no) 2001-07-19
CY1105609T1 (el) 2010-07-28
JP2002530319A (ja) 2002-09-17
AU767313B2 (en) 2003-11-06
NO20012514D0 (no) 2001-05-22
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
US6475524B1 (en) 2002-11-05
HUP0104182A2 (hu) 2002-03-28
AU2010400A (en) 2000-06-13
SE9804000D0 (sv) 1998-11-23
ES2258865T3 (es) 2006-09-01
DK1133285T3 (da) 2006-06-06
JP4447169B2 (ja) 2010-04-07

Similar Documents

Publication Publication Date Title
IL143040A0 (en) A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
CA2348084A1 (en) Crystallisation using supercritical or subcritical fluids
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
HUT63763A (en) Process for producing pharmaceutical composition comprising rapamycin, suitable for treating ophthalmia
WO2001041762A3 (en) Valdecoxib compositions
WO1996015786A3 (en) Oral compositions containing ondansetron
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
NO20002702L (no) Tienopyrimidiner
WO2002002056A3 (en) Method of treatment of seborrheic dermatitis
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
WO2003066071A8 (en) Formulations comprising psychotropic drugs and selenium
WO2000012045A3 (en) Method for treating neurodegenerative disorders
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
ATE99290T1 (de) Substituierte 4-amino-2-butinyl-harnstoffe und - thioharnstoffe sowie deren derivate als zentral wirkende muscarinische mittel.
WO2001042272A3 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
WO2004014391B1 (en) Use of carboxamides for the treatment of tinnitus
CA2279943A1 (en) Treatment of skin disorders
CN1069196C (zh) 利福平在制备治疗淋病用的药物中的应用
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
CA2423288A1 (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
SAKANO A clinical survey of spina bifida at Kagawa Prefectural Rehabilitation Center